A feedback loop of AI, molecular modelling and wet-laboratory experiments
- PentaBind has built the largest proprietary aptamer dataset of its kind and harnesses a suite of AI models with molecular modelling to design and optimise ‘drug-like’ aptamers.
- This platform powers our therapeutics pipeline, accelerating programs toward IND readiness.
- Our partnerships and services both validate and expand our AI aptamer design capabilities, while generating revenue and data that strengthen the pipeline
Refines the search space
on drug-like aptamers
- Reducing discovery time from 6 months to ~20 days
- Designs multiple aptamer characteritics simultaneously
- Refines search space from 10^35 to 10^2
- Isolates biases and errors in manual experiments
- Antibody discovery takes years with costly cell and animal work while PentaBind delivers drug-ready candidates in as little as 20 days
Real world results propel commercial aptamers
- AI designed aptamers have been validated in real world and by dozens of partners
- PentaBind saved 38 years of experimental time for a partner and designed 300x more aptamer candidates
- The real-world experiment to the right evaluated 10^8 aptamer sequences and confirmed PentaBind’s superior performance
PentaBind’s uniqueness-based selection outperformed our original candidates. Their AI identified an aptamer, now our best performer by a wide margin, that we would have overlooked under our previous enrichment methods"
